Design, analysis, and testing of the Phase 1 CSI Evolutionary Model erectable truss

This report addressed the design, analysis, and testing of the erectable truss structure for the Phase 1 CSI Evolutionary Model (CEM) testbed. The Phase 1 CEM testbed is the second testbed to form part of an ongoing program of focused research at NASA/LaRC in the development of Controls-Structures Integration (CSI) technology. The Phase 1 CEM contains the same overall geometry, weight, and sensor locations as the Phase 0 CEM, but is based in an integrated controller and structure design, whereby both structure and controller design variables are sized simultaneously. The Phase 1 CEM design features seven truss sections composed of struts with tailored mass and stiffness properties. A common erectable joint is used and the strut stiffness is tailored by varying the cross-sectional area. To characterize the structure, static tests were conducted on individual struts and 10-bay truss assemblies. Dynamic tests were conducted on 10-bay truss assemblies as well as the fully-assembled CEM truss. The results indicate that the static and dynamic properties of the structure are predictable, well-characterized, and within the performance requirements established during the Phase 1 CEM integrated controller/structure design analysis

Soluble receptor for advanced glycation end-product levels are related to albuminuria and arterial stiffness in essential hypertension

Background and aims: Emerging evidence suggests that the soluble receptor for advanced glycation end-products (sRAGE) is implicated in the development of vascular disease. We investigated the interrelationships of sRAGE with albumin to creatinine ratio (ACR) and arterial stiffness in essential hypertension. Methods and results: In 309 untreated non-diabetic hypertensives, ACR values were determined as the mean of three non-consecutive morning spot urine samples and aortic stiffness was evaluated on the basis of carotid to femoral pulse wave velocity (c-f PWV). In all subjects, venous blood sampling was performed for the estimation of sRAGE levels. Patients with low (n = 155) compared to those with high sRAGE values (n = 154) had greater 24-h systolic BP (140 ± 8 vs. 134 ± 7 mmHg, p < 0.0001), exhibited higher ACR (36.3 ± 51.6 vs. 17.2 ± 1.2 mg g-1, p < 0.0001) and c-f PWV (8.3 ± 1.5 vs. 7.8 ± 1.1 m s-1, p = 0.003), independently of confounding factors. Multiple regression analyses revealed that age, male sex, 24-h systolic BP and sRAGE were the 'independent correlates' of ACR (R2 = 0.493, p < 0.0001), while age, 24-h systolic BP and sRAGE were the 'independent correlates' of c-f PWV (R2 = 0.428, p < 0.0001). Conclusion: In hypertensives, decreased sRAGE levels are accompanied by pronounced albuminuria and arterial stiffening. The association of sRAGE with ACR and c-f PWV suggests involvement of sRAGE in the progression of hypertensive vascular damage. © 2011 Elsevier B.V